Colinz Laboratories share news, announcements and annual reports
BSE: 531210Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 29 Oct 2026. Previous close ₹69.00.
29 Oct: open ₹69.90, high ₹72.50, low ₹69.90
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹18 Cr4,457th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 6.34
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹2.76 crore of one-off items, the largest of them in the quarter to Jun 2026.
- 918.42
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.39
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 24.6%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹2.76 crore of one-off items, the largest of them in the quarter to Jun 2026.
- 0.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 1.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.04
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 1,613
Colinz Laboratories has 438 announcements on record, routine notices left out; 6 in the 30 days to 30 Oct 2026, the latest on 29 Oct 2026.
Last results date
The last board meeting held for results; the company has not yet given notice of the next.Colinz Laboratories quarterly results
The board met on 29 Oct 2026 to consider quarterly results
Notice filed 19 Oct 2026
Colinz Laboratories annual reports, presentations and earnings calls
The company's own documents, latest first.Colinz Laboratories financials, year by year
Annual reports26
- Annual report, year to Mar 202620 Aug 2026
- Annual report, year to Mar 202528 Aug 2025
- Annual report, year to Mar 202429 Aug 2024
- Annual report, year to Mar 202329 Aug 2023
- Annual report, year to Mar 202224 Aug 2022
21 earlier reports
- Annual report, year to Mar 202130 Aug 2021
- Annual report, year to Mar 20201 Sep 2020
- Annual report, year to Mar 201916 Oct 2019
- Annual report, year to Mar 201829 Sep 2018
- Annual report, year to Mar 20173 Oct 2017
- Annual report, year to Mar 201620 Sep 2016
- Annual report, year to Mar 201411 Sep 2014
- Annual report, year to Mar 201311 Dec 2013
- Annual report, year to Mar 201212 Jan 2013
- Annual report, year to Mar 201121 Dec 2011
- Annual report, year to Mar 2010Filing day not known
- Annual report, year to Mar 2009Filing day not known
- Annual report, year to Mar 2008Filing day not known
- Annual report, year to Mar 2006Filing day not known
- Annual report, year to Mar 2005Filing day not known
- Annual report, year to Mar 2004Filing day not known
- Annual report, year to Mar 2003Filing day not known
- Annual report, year to Mar 2002Filing day not known
- Annual report, year to Mar 2000Filing day not known
- Annual report, year to Mar 1999Filing day not known
- Annual report, year to Mar 1997Filing day not known
Colinz Laboratories share news and announcements
Newest first. Page 1 of 9.
Oct 2026
19 Oct · Board meeting
Meeting on 29 Oct 2026: quarterly results1 Oct · Declaration With Respect To Non-Applicability Of Related Party Transactions Pursuant To Regulations 23(9) Of The SEBI (Listing Obligations And Disclosure Requirements, Regulation 2015).
Sep 2026
4 Sep · Post Offer Advertisement
Aug 2026
12 Aug · Updates on Open Offer
6 Aug · Updates on Open Offer
Jul 2026
30 Jul · Outcome Of The Meeting Of Board Of Directors Was Held On Thursday, 30Th July, 2026 At 03:30 P.M. The Board Of Directors Discussed And/Or Approved The Following:
20 Jul · Board meeting
Meeting on 30 Jul 2026: quarterly results4 Jul · Draft Letter of Offer
3 Jul · Certificate Of Non-Applicability Of Regulation 27(2) Of Chapter IV Of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015 For The Quarter Ended On 30Th June , 2026 & Regulation 15(2)A Of Chapter IV.
3 Jul · Declaration With Respect To Non-Applicability Of Related Party Transactions Pursuant To Regulations 23(9) Of The SEBI (Listing Obligations And Disclosure Requirements, Regulation 2015).
Jun 2026
27 Jun · Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Receipt Of Final Tranche Of Consideration Towards Sale Of Factory Undertaking
27 Jun · Detailed Public Statement
18 Jun · Announcement under Regulation 30 (LODR)-Open Offer - Updates
18 Jun · Open Offer - Public Announcement
1 Jun · Legal
Exchange has sought clarification from Colinz Laboratories Ltd on June 1, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant ....
May 2026
Apr 2026
21 Apr · Board meeting
Meeting on 29 Apr 2026: quarterly results3 Apr · Declaration With Respect To Non-Applicability Of Related Party Transactions Pursuant To Regulations 23(9) Of The SEBI (Listing Obligations And Disclosure Requirements, Regulation 2015).
Jan 2026
19 Jan · Board meeting
Meeting on 24 Jan 2026: quarterly results17 Jan · Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
14 Jan · Board meeting
Meeting on 17 Jan 20262 Jan · Declaration With Respect To Non-Applicability Of Related Party Transactions Pursuant To Regulations 23(9) Of The SEBI (Listing Obligations And Disclosure Requirements, Regulation 2015) For The Quarter Ended 31St December, 2025.
How the price met the news
The first session after each announcement, beside the market.
That dayThe first session's move. The first session's close after the announcement against the close before it, as a per cent change, on prices adjusted for splits and bonuses.Against the Nifty 500Against the Nifty 500. The share's move less the Nifty 500's move the same session, in percentage points (pts).Market median on that newsThe market's median move on that news. The middle first-session move of every listed company that filed the same kind of announcement, half moving more and half less.Five sessionsFive sessions' move. The close five sessions after the announcement against the close before it, as a per cent change.Five sessions against the Nifty 500Five sessions against the Nifty 500. The share's five-session move less the Nifty 500's move over the same five sessions, in percentage points (pts).Volume, times usualVolume, times usual. The session's shares traded divided by the average of the twenty sessions before it.
- 22 May 2025Board or managers changedup 4.97%+5.6 pts vs Nifty 500market median 0.0% · five sessions +14.6% (+14.4 pts vs Nifty 500) · volume 2.1× usual · The announcement
- 3 Oct 2024Board or managers changeddown 0.02%+2.1 pts vs Nifty 500market median 0.0% · five sessions −2.2% (+0.5 pts vs Nifty 500) · volume 0.1× usual · The announcement
- 13 May 2019Board or managers changed–market median 0.0% · five sessions −4.7% (−4.0 pts vs Nifty 500) · volume 0.3× usual · The announcement